Citigroup Downgrades Calliditas Therapeutics to Neutral, Announces $39 Price Target
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has downgraded Calliditas Therapeutics (NASDAQ:CALT) from Buy to Neutral and set a price target of $39.
May 31, 2024 | 7:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup analyst Yigal Nochomovitz downgraded Calliditas Therapeutics from Buy to Neutral and set a price target of $39.
The downgrade from Buy to Neutral by a major financial institution like Citigroup is likely to negatively impact investor sentiment and could lead to a short-term decline in the stock price. The new price target of $39 also suggests limited upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100